Medicines for Alzheimer's disease can help with memory, thinking, and daily activities, while some newer treatments may slow the disease in its early stages. Common side effects include nausea, diarrhea, dizziness, headaches, and loss of appetite. Some newer treatments can cause serious brain swelling or bleeding, so doctors carefully assess their risks and monitor people receiving them.
Which medicines are used to treat Alzheimer's disease?
Alzheimer's disease is a progressive brain condition that affects memory, thinking, behavior, and the ability to manage everyday tasks. Medicines cannot cure it, but different treatments can help manage its effects.
The main medicines fall into three groups:
- Cholinesterase inhibitors: Donepezil, rivastigmine, and galantamine help brain cells communicate and may temporarily improve or stabilize certain symptoms.
- Glutamate regulators: Memantine helps regulate a brain chemical involved in learning and memory. It is generally used for moderate to severe Alzheimer's disease.
- Anti-amyloid treatments: Lecanemab and donanemab target amyloid protein deposits in the brain and can slow cognitive decline in some people with early Alzheimer's disease.
According to the Alzheimer's Association, medicines that manage symptoms and treatments that affect disease progression have different purposes. Choosing between them depends on the person's diagnosis, stage of illness, other health conditions, and treatment goals.
Donepezil, rivastigmine, and galantamine: Benefits and side effects
Donepezil, rivastigmine, and galantamine belong to a group called cholinesterase inhibitors. These medicines help maintain levels of acetylcholine, a chemical that allows nerve cells to send messages to one another.
They may help with memory, attention, communication, and certain everyday tasks. Their effects are usually modest, and they do not stop the underlying brain changes caused by Alzheimer's disease.
Donepezil (Aricept)
Donepezil is used to treat symptoms of mild, moderate, and severe Alzheimer's disease. It is generally taken by mouth once daily, although the prescribed formulation and dose depend on clinical circumstances.
Possible side effects include:
- Nausea and vomiting
- Diarrhea
- Difficulty sleeping or unusual dreams
- Muscle cramps
- Reduced appetite and weight loss
- Fatigue
Donepezil can also slow the heart rate in some people, potentially causing fainting. This is especially important for people with certain heart conditions or those taking other medicines that affect heart rhythm.
Rivastigmine (Exelon)
Rivastigmine is available in oral preparations and as a skin patch. The patch delivers medicine through the skin and may be useful when swallowing tablets is difficult or oral treatment causes troublesome digestive effects.
Common side effects include nausea, vomiting, diarrhea, loss of appetite, and weight loss. The skin patch may also cause itching or redness where it is applied.
Caregivers should follow patch instructions carefully. An old patch must be removed before a new one is applied because using multiple patches can result in too much medicine entering the body.
Galantamine (Razadyne)
Galantamine is used mainly for mild to moderate Alzheimer's disease. It increases the availability of acetylcholine and helps support communication between nerve cells.
Possible side effects include nausea, vomiting, diarrhea, headache, dizziness, and reduced appetite. Weight loss can also occur, particularly when digestive symptoms continue.
Galantamine is available in different oral formulations, and the dosing schedule depends on the prescribed product.
Do cholinesterase inhibitor side effects improve?
Many digestive side effects are most noticeable when treatment begins or the dose increases. According to the NHS, nausea, vomiting, and appetite changes associated with these medicines often improve after about two weeks.
Doctors commonly begin with a lower dose and increase it gradually when appropriate. Persistent vomiting, poor food intake, noticeable weight loss, fainting, or other concerning effects should be discussed with the prescribing clinician rather than managed by changing the dose independently.
Memantine: How it works and what side effects to expect
Memantine (Namenda) is generally prescribed for moderate to severe Alzheimer's disease. Unlike cholinesterase inhibitors, it acts on glutamate, a chemical involved in brain signaling.
Memantine may help some people maintain attention, thinking abilities, or everyday functions for a period of time. It may be prescribed alone or together with a cholinesterase inhibitor.
Common side effects include:
- Dizziness
- Headache
- Constipation
- Confusion
- Occasional digestive discomfort
Dizziness may increase the risk of falls, particularly in older adults who already have balance or walking difficulties.
Kidney function is another important consideration because memantine is cleared largely through the kidneys. People with significant kidney impairment may require a different dose.
Doctors consider changes in thinking, behavior, daily activities, and medication tolerance when deciding whether memantine is providing a useful benefit.
New Alzheimer's medicines that may slow disease progression
Anti-amyloid medicines represent a different approach to Alzheimer's treatment. Rather than only addressing symptoms, they target amyloid-beta, a protein that can form abnormal deposits in the brain.
Lecanemab and donanemab have received approval from the US Food and Drug Administration for treatment of early Alzheimer's disease. They are intended for selected people with mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, with evidence of amyloid buildup.
These medicines do not reverse existing memory loss or cure Alzheimer's disease. Clinical studies have shown that they can slow worsening of thinking and daily function in some eligible patients.
The Alzheimer's Association's treatment guidance explains the importance of confirming amyloid deposits and carefully reviewing eligibility before starting disease-modifying treatment.
Lecanemab (Leqembi)
Lecanemab is an antibody treatment that helps remove amyloid-beta deposits from the brain. It is administered through intravenous infusions or, for eligible patients, an approved under-the-skin injection regimen. The schedule depends on the formulation and treatment phase.
Possible side effects include headache, infusion-related reactions, fever, chills, nausea, and changes seen on brain scans.
Its most important safety concern is amyloid-related imaging abnormalities, commonly called ARIA. These changes can involve swelling or bleeding in the brain and may occasionally be serious or life-threatening.
According to MedlinePlus, a service of the US National Library of Medicine, people receiving lecanemab need monitoring with magnetic resonance imaging (MRI) scans before and during treatment. Certain inherited genetic factors and medicines that increase bleeding risk may affect treatment safety.
Donanemab (Kisunla)
Donanemab is another antibody medicine that targets amyloid deposits. It is given as an intravenous infusion, generally every four weeks, under medical supervision.
Potential side effects include headaches, infusion reactions, and ARIA. Some people may experience confusion, dizziness, or vision changes associated with brain swelling or bleeding.
According to MedlinePlus, donanemab can cause serious infusion reactions and amyloid-related brain abnormalities. MRI monitoring and careful evaluation of bleeding risks are important parts of treatment.
Availability, approved uses, monitoring requirements, and treatment costs vary by country. These treatments are not appropriate for everyone with Alzheimer's disease, and decisions about their use require specialist assessment.
Which Alzheimer's medicine side effects need urgent attention?
Most medication side effects are manageable, but certain symptoms require prompt medical assessment.
Warning signs during anti-amyloid treatment
People receiving lecanemab or donanemab should seek immediate medical attention for new or concerning neurological symptoms, including:
- Sudden or severe headache
- New or marked confusion
- Changes in vision
- Difficulty speaking
- New weakness or problems with walking
- Seizures
- Sudden loss of balance
These symptoms may have several causes, but in someone receiving anti-amyloid treatment they can be associated with serious complications. Emergency assessment should not be delayed.
Other serious medication reactions
Fainting, a very slow heartbeat, severe or persistent vomiting, or marked dehydration during treatment with a cholinesterase inhibitor also requires prompt assessment.
Swelling of the face or throat, severe breathing difficulty, or collapse may indicate a serious allergic reaction and requires emergency medical care.
Medicines for agitation and behavioral changes in Alzheimer's disease
Some people with Alzheimer's disease experience agitation, aggression, anxiety, disturbed sleep, or other behavioral changes. These difficulties may be associated with discomfort, pain, medication effects, environmental stress, or progression of the disease.
Before prescribing additional medicines, clinicians generally review possible causes and consider approaches such as adjusting routines, reducing environmental triggers, and addressing unmet needs.
In the United States, brexpiprazole is approved to treat agitation associated with dementia due to Alzheimer's disease. Other antipsychotic medicines may sometimes be considered when symptoms are particularly distressing or create a risk of harm.
However, antipsychotics carry important risks in older people with dementia, including an increased risk of death and certain serious medical complications. Their use requires careful evaluation, monitoring, and discussion of benefits and risks.
Medication for behavioral symptoms should not automatically replace attempts to understand and address the reasons for the behavior.
How doctors choose the safest Alzheimer's medicine
There is no single Alzheimer's medicine that works best for everyone. Treatment selection depends on the person's symptoms, confirmed diagnosis, medical history, current medications, and ability to tolerate treatment.
Important factors include:
- Stage of illness: Cholinesterase inhibitors, memantine, and anti-amyloid medicines have different approved uses and treatment goals.
- Heart conditions: Certain medicines may slow the heart rate or increase the risk of fainting.
- Kidney function: Impaired kidney function can affect the appropriate dose of memantine.
- Body weight and nutrition: Medicines that reduce appetite or cause vomiting may be more difficult to tolerate when weight loss is already a concern.
- Bleeding risk: Anti-amyloid treatments require particular attention to bleeding disorders, brain imaging findings, and medicines that affect blood clotting.
- Ability to follow treatment: Swallowing difficulties, memory problems, caregiver support, and monitoring requirements can influence the preferred formulation.
For anti-amyloid treatment, specialists may use amyloid testing, brain MRI scans, and genetic risk information to evaluate eligibility and discuss possible complications.
Although Alzheimer's disease most often affects older adults, treatment decisions are not based on age alone. Younger adults with early-onset Alzheimer's may also be considered for appropriate treatments, depending on the diagnosis and the eligibility requirements for each medicine.
Practical ways to manage common medicine side effects
Side effects should be discussed with the prescribing clinician, especially when they interfere with eating, sleeping, walking, or daily care. Some practical steps can make treatment safer and easier to manage.
Keep track of new symptoms
Record when a symptom begins, whether it follows a dose change, and how it affects daily activities. A caregiver's observations may be especially useful when the person has difficulty describing what they feel.
Follow the prescribed dosing schedule
Take medicines exactly as directed. Do not double doses after a missed tablet or apply extra patches. Different formulations have different instructions, so consult the medicine leaflet, pharmacist, or prescribing clinician.
Discuss ongoing digestive problems
For nausea, vomiting, diarrhea, or appetite loss, a clinician may review the dose, timing, formulation, or choice of medicine. Regular weight checks may help identify unwanted weight loss.
Reduce fall-related risks
If dizziness occurs, caregivers can help by providing support when standing or walking and keeping frequently used areas free of obstacles. New or significant dizziness should also be assessed medically.
Review all other medicines
Prescription medicines, over-the-counter products, vitamins, and herbal supplements should be included in medication reviews. Some products may interact with Alzheimer's treatments or increase the risk of unwanted effects.
Attend monitoring appointments
Follow-up visits allow doctors to assess whether treatment remains useful and whether adverse effects are developing. For people receiving lecanemab or donanemab, scheduled MRI monitoring is a particularly important safety requirement.
How can families tell whether Alzheimer's medicine is helping?
The benefits of treatment are not always obvious from day to day. Some medicines may help a person remain more engaged, communicate more easily, or continue certain activities for longer.
Families can share observations about memory, conversations, daily routines, independence, sleep, appetite, and behavior during follow-up appointments.
Doctors may also use cognitive assessments and functional evaluations to look for changes over time. The goal is to understand whether the possible benefits remain worthwhile compared with side effects and treatment burden.
For anti-amyloid medicines, slowing the rate of decline is different from improving lost abilities. A person may continue to experience changes in memory or daily functioning even when treatment is having a beneficial effect.
If a medicine appears ineffective or difficult to tolerate, the prescribing clinician may reconsider the treatment plan. Families should not stop or change prescribed Alzheimer's medicines without medical guidance.
What should patients and caregivers remember?
Alzheimer's medicines offer different benefits and carry different risks. Donepezil, rivastigmine, galantamine, and memantine mainly help manage symptoms. Lecanemab and donanemab may slow progression in selected people with early Alzheimer's disease but require closer monitoring because of potentially serious complications.
Understanding the expected benefits, recognizing side effects, and keeping regular medical appointments can help patients and families make informed treatment decisions. A neurologist or another clinician experienced in dementia care can explain which options are appropriate and when treatment should be reassessed.